■Dupilumab是特应性皮炎(AD)的第一种生物治疗方法。Dupilumab相关眼表疾病(DAOSD)是dupilumab治疗期间AD患者中最常见的副作用之一。这项研究旨在在现实世界中识别DAOSD的风险因素,并构建用于预测DAOSD风险的风险评分系统。
对2019年4月至2023年9月在韩国YeouidoSt.Mary医院接受dupilumab治疗的成年AD患者进行了回顾性分析。包括接受dupilumab治疗AD的年龄≥18岁的患者。进行单变量和多变量逻辑回归分析以确定DAOSD的独立危险因素。基于显著变量的调整后的奇数比率,构建了一个风险评分系统来预测DAOSD风险。
■在97名接受dupilumab治疗的患者中,28(28.9%)发展了DAOSD。其中,3例(10.7%)患者因眼部副作用而停用dupilumab.在多变量分析中,年龄较大,结膜炎史,基线湿疹面积和严重程度指数(EASI)评分≥28是发生DAOSD的独立危险因素.使用这些变量,建立了风险评分系统。预测的DAOSD风险为0,1,2,3,4和5分的AD患者为5.8%,14.2%,30.7%,54.3%,76.2%,和89.6%,分别。
■在这项研究中,病人的年龄,结膜炎史,较高的基线EASI评分与DAOSD显著相关。这种风险评分系统将有助于识别在开始dupilumab治疗时需要更加谨慎的高风险患者。
UNASSIGNED: Dupilumab is the first biological treatment for atopic dermatitis (AD). Dupilumab-associated ocular surface disease (
DAOSD) is one of the most commonly reported side effects in patients with AD during dupilumab treatment. This study aimed to identify risk factors for
DAOSD in a real-world setting and construct a risk-scoring system for predicting
DAOSD risk.
UNASSIGNED: A retrospective analysis was conducted for dupilumab-treated adult patients with AD between April 2019 and September 2023 at Yeouido St. Mary\'s Hospital in Korea. Patients aged ≥18 years who received dupilumab to treat AD were included. Univariate and multivariable logistic regression analyses were performed to determine independent risk factors for
DAOSD. A risk scoring system was constructed to predict DAOSD risk based on the adjusted odd ratios of significant variables.
UNASSIGNED: Of the 97 dupilumab-treated patients, 28 (28.9%) developed
DAOSD. Among them, three (10.7%) patients discontinued dupilumab due to ocular side effects. In the multivariable analysis, older age, history of conjunctivitis, and a baseline Eczema Area and Severity Index (EASI) score ≥28 were independent risk factors for developing DAOSD. Using these variables, a risk-scoring system was constructed. The predicted DAOSD risks for AD patients with 0, 1, 2, 3, 4, and 5 points were 5.8%, 14.2%, 30.7%, 54.3%, 76.2%, and 89.6%, respectively.
UNASSIGNED: In this study, the patient\'s age, history of conjunctivitis, and higher baseline EASI score were significantly associated with DAOSD. This risk-scoring system would help identify high-risk patients requiring more caution when initiating dupilumab treatment.